Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
Ceribell, Inc. reported that the U.S. Food and Drug Administration granted 510(k) clearance for its Clarity® algorithm to detect electrographic seizures in newborns, preterm and older. This clearance allows Ceribell to market the Clarity algorithm for this specific clinical use in neonatal patients. The company disclosed the news through a press release, which is attached as an exhibit to this current report.
Ceribell (CBLL)
CeriBell (CBLL) reported Q3 2025 results with total revenue of $22.589 million, up from $17.195 million a year ago, driven by product revenue of $17.020 million and subscription revenue of $5.569 million. Gross profit was $19.942 million.
Operating expenses rose to $34.589 million, leading to a net loss of $13.465 million (basic and diluted loss per share $0.37). For the nine months, revenue reached $64.279 million with a net loss of $39.885 million.
Liquidity remained strong with $168.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025 (
Ceribell, Inc. (CBLL) furnished an update on its latest performance, announcing that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company stated that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act, nor incorporated by reference under the Securities Act unless specifically referenced.
CeriBell, Inc. filed a universal shelf registration to offer up to $300,000,000 of securities — including common stock, preferred stock, debt securities, warrants, and units — to be sold from time to time in one or more offerings. A prospectus supplement will set the specific amounts, prices, and terms for each takedown and may update the base disclosures.
The company may sell through underwriters, dealers, agents, directly to purchasers, or a combination of these methods. Use of proceeds will be described in the applicable supplement. CeriBell’s common stock trades on the Nasdaq Global Select Market under “CBLL”; the last reported price was $11.34 per share on November 3, 2025.
Ceribell, Inc. (CBLL) insider activity on
Mr. Woo exercised 1,472 options at a
Ceribell, Inc. (CBLL) notice reports proposed and completed insider sales of common stock. An insider planned to sell 11,112 shares through Fidelity Brokerage Services LLC with an aggregate market value of $139,314.51, and the filing lists 36,663,968 shares outstanding. The securities to be sold were acquired via stock options granted on 07/07/2021 (1,472 shares) and 02/16/2023 (9,640 shares), with payment noted as cash. The form also discloses a completed sale by Raymond Woo of 11,112 shares on 09/04/2025 for gross proceeds of $134,609.74. The filer certifies no undisclosed material adverse information and includes standard Rule 144 and Rule 10b5-1 notices.
Ceribell, Inc. reports updates to its long-term supply relationship with Shenzhen Everwin Precision Technology. The existing Corporate Supply Agreement, originally signed in January 2022, covers supply of Ceribell’s small and large headbands and licenses product materials needed to manufacture and support these products.
Amendment No. 1 extended the initial two-year term to January 9, 2025, and Amendment No. 2 further extended the term to December 31, 2027 while designating Everwin Precision Holding (Hong Kong) Company Limited as agent and providing for deliveries from a facility in Tijuana, Mexico. On September 22, 2025, Amendment No. 3 added Everwin Precision (Viet Nam) Technology as an additional agent of Everwin China to enable deliveries of headbands from a facility in Vietnam.
Ceribell, Inc. reported that, effective September 17, 2025, its Board of Directors elected Erica Rogers to serve as a director until the next annual meeting of stockholders and until a successor is duly elected and qualified, or her earlier resignation or removal.
She has also been appointed to the Board’s Compensation Committee. As a non-employee director, Ms. Rogers will receive annual cash compensation and restricted stock units under Ceribell’s Non-Employee Director Compensation Program, and the company will enter into its standard-form indemnification agreement with her. The company states there is no arrangement or understanding with any other person regarding her election and that she is not involved in related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Ceribell director Erica J. Rogers filed an initial Form 3 reporting her relationship to Ceribell, Inc. (CBLL) with an event date of 09/17/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Louisa Daniels, on 09/19/2025, and includes Exhibit 24 (Power of Attorney).